Predictive factors for risk of chronic evolution in Vogt–Koyanagi–Harada disease at 1 month after pulse steroid therapy
PLOS One · 11.11.2026 · 21 (11) · e0362558
DOI: 10.1371/journal.pone.0362558 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 11.11.2026. Verfasst von Tetsuya Muto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan. Hauptthemen laut MEDLINE: Uveomeningoencephalitic Syndrome, Steroids. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this study, we aimed to identify factors for risk of chronic evolution in Vogt–Koyanagi–Harada (VKH) disease at 1 month following pulse steroid therapy. This was a retrospective clinical cohort, single center study. A total of 121 eyes from 61 treatment-naïve patients with acute VKH disease, who underwent pulse steroid therapy and had follow-up for over 12 months were evaluated. Patients were categorized into SGF and non-SGF groups according to fundus outcomes at 12 months after treatment. Anterior chamber morphology was assessed using Pentacam ® , while axial length and lens thickness were measured with the IOLMaster 700. Multivariable analysis demonstrated that lower best-corrected visual acuity (BCVA) ( p < 0.001) and increased corneal thickness ( p = 0.016) at 1 month were significantly associated with the development of SGF. Receiver operating characteristic curve analysis determined optimal cut-off values for predicting SGF as a logarithmic BCVA greater than −0.040 and a corneal thickness exceeding 574.500 µm. The corresponding Youden index values were 0.291 for BCVA and 0.244 for corneal thickness. Elevated logarithmic BCVA values and increased corneal thickness at 1 month after treatment were identified as risk factors for the subsequent SGF development. Applying higher cut-off values for these factors may facilitate more targeted therapeutic strategies in patients with VKH disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
- Imaizumi Eye Hospital, Koriyama, Japan.
- Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
ORCID-Profile: Tetsuya Muto
Zitieren
APA
Muto, T., Kusuda, S., Sakamoto, M., Machida, S., Imaizumi, S., & Sekiryu, T. (2026). Predictive factors for risk of chronic evolution in Vogt–Koyanagi–Harada disease at 1 month after pulse steroid therapy. PLOS One, 21(11), e0362558. https://doi.org/10.1371/journal.pone.0362558
Vancouver
Muto T, Kusuda S, Sakamoto M, Machida S, Imaizumi S, Sekiryu T. Predictive factors for risk of chronic evolution in Vogt–Koyanagi–Harada disease at 1 month after pulse steroid therapy. PLOS One. 2026;21(11):e0362558. doi:10.1371/journal.pone.0362558
BibTeX
@article{Muto2026,
author = {Muto, Tetsuya and Kusuda, Shoichiro and Sakamoto, Masaaki and Machida, Shigeki and Imaizumi, Shinichiro and Sekiryu, Tetsuju},
title = {Predictive factors for risk of chronic evolution in Vogt–Koyanagi–Harada disease at 1 month after pulse steroid therapy},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {11},
pages = {e0362558},
doi = {10.1371/journal.pone.0362558}
}
EUVIMED